BMO Capital on Structure Therapeutics (GPCR): 'Licensing agreement with Genentech is not the large Pharma partnership that some Structure owners have been anxiously awaiting'
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $130.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
